Last updated on June 2005

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: HIV Infections
  • Age: Between 1 - 17 Years
  • Gender: Male or Female
  • Other:
    Children may be eligible for this study if they:
    Are at least 3 months old and no older than 17 years of age. This is the age the
    child needs to be at the time they begin the study.
    Are HIV positive.
    Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of
    gestation.
    Have or have not taken anti-HIV drugs. Those that have not must have a viral load
    between 5,000 and 500,000 copies/ml at screening. Those that have must have been
    taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral
    load of no more than 400 copies/ml at screening.
    Have a CD4 count of more than 200 cells/mm3.
    Have written consent from parent or guardian.
    Are willing to use effective birth control during the study and for 1 month after the
    last dose of emtricitabine, if sexually active.
    Children may be eligible for this study if they:
    Are at least 3 months old and no older than 17 years of age. This is the age the
    child needs to be at the time they begin the study.
    Are HIV positive.
    Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of
    gestation.
    Have or have not taken anti-HIV drugs. Those that have not must have a viral load
    between 5,000 and 500,000 copies/ml at screening. Those that have must have been
    taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral
    load of no more than 400 copies/ml at screening.
    Have a CD4 count of more than 200 cells/mm3.
    Have written consent from parent or guardian.
    Are willing to use effective birth control during the study and for 1 month after the
    last dose of emtricitabine, if sexually active.
    Children may be eligible for this study if they:
    Are at least 3 months old and no older than 17 years of age. This is the age the
    child needs to be at the time they begin the study.
    Are HIV positive.
    Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of
    gestation.
    Have or have not taken anti-HIV drugs. Those that have not must have a viral load
    between 5,000 and 500,000 copies/ml at screening. Those that have must have been
    taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral
    load of no more than 400 copies/ml at screening.
    Have a CD4 count of more than 200 cells/mm3.
    Have written consent from parent or guardian.
    Are willing to use effective birth control during the study and for 1 month after the
    last dose of emtricitabine, if sexually active.
    Children may be eligible for this study if they:
    Are at least 3 months old and no older than 17 years of age. This is the age the
    child needs to be at the time they begin the study.
    Are HIV positive.
    Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of
    gestation.
    Have or have not taken anti-HIV drugs. Those that have not must have a viral load
    between 5,000 and 500,000 copies/ml at screening. Those that have must have been
    taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral
    load of no more than 400 copies/ml at screening.
    Have a CD4 count of more than 200 cells/mm3.
    Have written consent from parent or guardian.
    Are willing to use effective birth control during the study and for 1 month after the
    last dose of emtricitabine, if sexually active.
    Children may be eligible for this study if they:
    Are at least 3 months old and no older than 17 years of age. This is the age the
    child needs to be at the time they begin the study.
    Are HIV positive.
    Weigh more than 5.5 pounds. A newborn child must have reached at least 38 weeks of
    gestation.
    Have or have not taken anti-HIV drugs. Those that have not must have a viral load
    between 5,000 and 500,000 copies/ml at screening. Those that have must have been
    taking anti-HIV drugs, including lamivudine, for at least 3 months and have a viral
    load of no more than 400 copies/ml at screening.
    Have a CD4 count of more than 200 cells/mm3.
    Have written consent from parent or guardian.
    Are willing to use effective birth control during the study and for 1 month after the
    last dose of emtricitabine, if sexually active.

You may not be eligible for this study if the following are true:

  • Children will not be eligible for this study if they:
    Are pregnant or breast-feeding.
    Cannot follow the visit or dosing schedule or are not available for 1 year.
    Have taken experimental drugs or vaccines (except for emivirine and experimental
    forms of approved drugs) within 30 days of study start.
    Have nerve damage in their arms or legs.
    Have trouble eating or taking drugs.
    Have serious diarrhea within 30 days before study entry.
    Have had any serious illness within 30 days of study screening. Any treatment must
    have been finished 14 days before study entry.
    Have had an AIDS-related (opportunistic) disease within 12 months of screening.
    Are being treated for tuberculosis.
    Have had pancreatitis.
    Require certain drugs.
    Children will not be eligible for this study if they:
    Are pregnant or breast-feeding.
    Cannot follow the visit or dosing schedule or are not available for 1 year.
    Have taken experimental drugs or vaccines (except for emivirine and experimental
    forms of approved drugs) within 30 days of study start.
    Have nerve damage in their arms or legs.
    Have trouble eating or taking drugs.
    Have serious diarrhea within 30 days before study entry.
    Have had any serious illness within 30 days of study screening. Any treatment must
    have been finished 14 days before study entry.
    Have had an AIDS-related (opportunistic) disease within 12 months of screening.
    Are being treated for tuberculosis.
    Have had pancreatitis.
    Require certain drugs.
    Children will not be eligible for this study if they:
    Are pregnant or breast-feeding.
    Cannot follow the visit or dosing schedule or are not available for 1 year.
    Have taken experimental drugs or vaccines (except for emivirine and experimental
    forms of approved drugs) within 30 days of study start.
    Have nerve damage in their arms or legs.
    Have trouble eating or taking drugs.
    Have serious diarrhea within 30 days before study entry.
    Have had any serious illness within 30 days of study screening. Any treatment must
    have been finished 14 days before study entry.
    Have had an AIDS-related (opportunistic) disease within 12 months of screening.
    Are being treated for tuberculosis.
    Have had pancreatitis.
    Require certain drugs.
    Children will not be eligible for this study if they:
    Are pregnant or breast-feeding.
    Cannot follow the visit or dosing schedule or are not available for 1 year.
    Have taken experimental drugs or vaccines (except for emivirine and experimental
    forms of approved drugs) within 30 days of study start.
    Have nerve damage in their arms or legs.
    Have trouble eating or taking drugs.
    Have serious diarrhea within 30 days before study entry.
    Have had any serious illness within 30 days of study screening. Any treatment must
    have been finished 14 days before study entry.
    Have had an AIDS-related (opportunistic) disease within 12 months of screening.
    Are being treated for tuberculosis.
    Have had pancreatitis.
    Require certain drugs.
    Children will not be eligible for this study if they:
    Are pregnant or breast-feeding.
    Cannot follow the visit or dosing schedule or are not available for 1 year.
    Have taken experimental drugs or vaccines (except for emivirine and experimental
    forms of approved drugs) within 30 days of study start.
    Have nerve damage in their arms or legs.
    Have trouble eating or taking drugs.
    Have serious diarrhea within 30 days before study entry.
    Have had any serious illness within 30 days of study screening. Any treatment must
    have been finished 14 days before study entry.
    Have had an AIDS-related (opportunistic) disease within 12 months of screening.
    Are being treated for tuberculosis.
    Have had pancreatitis.
    Require certain drugs.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.